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Antibody deficiency or hypogammaglobulinemia can have primary or secondary
etiologies. Primary antibody deficiency (PAD) is the result of intrinsic genetic defects,
whereas secondary antibody deficiency may arise as a consequence of underlying
conditions or medication use. On a global level, malnutrition, HIV, and malaria are major
causes of secondary immunodeficiency. In this review we consider secondary antibody
deficiency, for which common causes include hematological malignancies, such as
chronic lymphocytic leukemia or multiple myeloma, and their treatment, protein-losing
states, and side effects of a number of immunosuppressive agents and procedures
involved in solid organ transplantation. Secondary antibody deficiency is not only much
more common than PAD, but is also being increasingly recognized with the wider and
more prolonged use of a growing list of agents targeting B cells. SAD may thus present
to a broad range of specialties and is associated with an increased risk of infection. Early
diagnosis and intervention is key to avoidingmorbidity andmortality. Optimizing treatment
requires careful clinical and laboratory assessment and may involve close monitoring of
risk parameters, vaccination, antibiotic strategies, and in some patients, immunoglobulin
replacement therapy (IgRT). This review discusses the rapidly evolving list of underlying
causes of secondary antibody deficiency, specifically focusing on therapies targeting B
cells, alongside recent advances in screening, biomarkers of risk for the development of
secondary antibody deficiency, diagnosis, monitoring, and management.
Keywords: secondary antibody deficiency, chronic lymphocytic leukemia, lymphoma, multiple myeloma, solid
organ transplant, immunoglobulin replacement (IgRT)
INTRODUCTION
Antibody deficiencies, a subset of immunodeficiencies, are classified as primary or secondary in
etiology. Primary antibody deficiency (PAD) refers to a heterogeneous group of genetic disorders
characterized by an intrinsic impairment in antibody production or function (1, 2). The prevalence
of PAD has been estimated to be around 1 in 2,000 children, 1 in 1,200 individuals of any
age, and 1 in 600 households in the United States (∼150,000–360,000 patients) (3). Secondary
immunodeficiencies (SID) on a worldwide scale occur as a consequence of an extrinsic influences,
such as malnutrition, human immunodeficiency virus (HIV) infection, malaria, neutropenia, or
as a side effect of certain medications (4). Secondary antibody deficiency, a type of SID, is often
multifactorial in etiology, related to both the underlying condition and its treatment, including
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a growing range of treatments targeting B cells. Secondary
antibody deficiency occurs across a broad wide disease spectrum,
and is therefore of importance to clinicians in both primary
and secondary care. Secondary antibody deficiencies are can be
estimated to be 30-fold more common than PADs, but unlike
PADs are sometimes reversible if the underlying cause is resolved
(4). There are several types of secondary antibody deficiency,
the most common being disease-related secondary antibody
deficiency, caused by hematologic malignancies such as chronic
lymphocytic leukemia (CLL), lymphoma, and multiple myeloma
(MM). Other types of secondary antibody deficiency include
iatrogenic secondary antibody deficiency as a side effect of
specific therapies designed to target B cells directly as well as non-
B cell specific therapies or processes which nonetheless impact on
B cells or antibodies including conventional immunosuppressive
agents (e.g., cyclophosphamide, methotrexate, mycophenolate
mofetil) steroids, radiation therapy, solid organ transplantation
(SOT), and secondary antibody deficiency related to protein-
losing states due to renal, gastrointestinal, or cutaneous loss
(Figure 1) (2, 4–6). Patients with secondary antibody deficiency
due to renal or gastrointestinal loss of IgG often have retained
specific antibody production and hence may have a lower
infection risk when compared to a failure to produce antibodies
(2). The removal of antibodies by plasma exchange or blockade
of the neonatal Fc receptor (FcRn) is also likely to confer a lower
risk of infection than deficiencies in antibody production (7–10).
The spectrum of clinical impact of secondary antibody
deficiency may range from a rather limited infection
FIGURE 1 | Common causes of secondary antibody deficiency (26), (5), (251), (255), (256), (242), (6), (144), (7), (165), (70), (242), (18), (168), (244), (134), (141), (135),
(139), (133), (155), (245), (147), (138), (38), (162), (124), (163), (246), (174), (233), (253), (257), (247), (252), (249), (250), (10), (254). Reproduced with the permission of
the copyright holder John Wiley & Sons Inc (5). *Including non-Hodgkin’s lymphoma, Hodgkin’s Lymphoma, diffuse large B cell lymphoma, follicular lymphoma, mantle
cell lymphoma, marginal zone lymphoma, and Burkitt’s lymphoma (5).
susceptibility to a more significant burden characterized by
predominantly sinopulmonary recurrent, chronic, systemic,
or complicated infections or even including opportunistic
infections, such as cytomegalovirus (CMV) in transplantation
(5). Although secondary antibody deficiency is a recognized
phenomenon, there are only a limited number of studies
addressing the incidence and clinical importance of this disorder
(11) and treatment outcomes have not been fully explored.
The prevalence of secondary antibody deficiency, which is
estimated to be 30 times more common than PAD (12–15), is
increasing for a number of reasons. Growth in new therapies
for autoimmune, inflammatory, and malignant disease, many
targeting B cells, is rapid. It is being increasingly appreciated
that the use of such therapies, such as rituximab, alongside high-
dose, and long-term steroid treatment, either in combination
with other treatments, sequentially over time or as maintenance
therapies may contribute to the increased development of
iatrogenic secondary antibody deficiency (5, 6). Studies report
an increased risk of infection with B cell-targeting drugs such
as rituximab or ibrutinib, and with long-term steroid treatment
(16, 17). It is becoming increasingly important to address the
unmet needs in this growing patient population, including risk
factors for the development of secondary antibody deficiency,
improved screening, monitoring, and treatment strategies.
The clinical management of secondary antibody deficiency
involves a range of potential interventions based on a careful
clinical and laboratory assessment of risk and may include
patient education, prompt access to emergency antibiotics,
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FIGURE 2 | B cell-specific chemotherapeutic causes of secondary antibody deficiency. Reproduced with the permission of the copyright holder The Royal College of
Physicians (2). *Anti-CD20 compounds conjugated to other drugs are also in development. APRIL, a proliferation inducing ligand; BAFF(-R), B-cell activating factor
(receptor); Bcl2, B cell lymphoma 2; BCMA, B-cell maturation antigen; (s)BCR, (surface) B cell receptor; TACI, transmembrane activator, and calcium modulator.
prophylactic antibiotic treatment, vaccination, and reducing
immunosuppression or treating the underlying cause in the small
proportion where this is possible. A trial of immunoglobulin
replacement therapy (IgRT) may be warranted for selected
patients with low immunoglobulin G (IgG;<4 g/L) who continue
to suffer recurrent infections despite prophylactic antibiotics and
who fail to respond to vaccination. Available studies report IgRT
as an effective treatment for reducing the rate of serious infections
in patients with CLL or MM (17–19). Recent market research
of secondary specialty pharmacy data from the United States,
France, the United Kingdom, Germany, Spain, Australia and
Canada reported that the major secondary antibody deficiency
indications leading to IgRT usage were CLL and MM, which
represent 39.2–54.9% of all patients with secondary antibody
deficiency receiving IgRT (20).
In this review, we discuss the causes, diagnosis, and
management of secondary antibody deficiency, specifically
focusing on new developments in agents targeting B cells
(Figures 1, 2).
CAUSES OF SECONDARY ANTIBODY
DEFICIENCY
CLL, MM, and Lymphoma
Hematological malignancies such as CLL, MM, and lymphoma
are commonly associated with hypogammaglobulinemia. CLL is
one of the most common leukemias, with an annual incidence
of 4.7 in 100,000 (15). Infection frequency in CLL correlates
positively with hypogammaglobulinemia, which is present in
up to 85% of these patients and contributes substantially to
morbidity and mortality, with infection-related deaths in 25–
50% of patients (13). The prevalence of hypogammaglobulinemia
in CLL is more pronounced with prolonged disease duration
and advanced-stage disease and correlates with patient age and
comorbidities (13).
Multiple myeloma has an annual incidence of 6.6 cases per
100,000 persons in the United States (14). Secondary antibody
deficiency is also common in MM, occurring in 45–83% of
patients with smoldering MM at some point during the disease
course (21). Infections in such patients are predominantly caused
by encapsulated bacteria, such as certain strains of Haemophilus
influenzae, however overall susceptibility is wide and includes
Clostridium difficile and Escherichia coli, Staphylococcus aureus,
and fungal and viral infections, such as Varicella Zoster virus
(VZV) (6, 22). One study of more than 3,000 patients with
MM demonstrated that infection was responsible for 45%
of deaths within 6 months of diagnosis. Respiratory tract
infections (RTIs) are noted most frequently, with pneumonia,
septicemia, and urinary tract infections (UTIs) also occurring
commonly in this patient population (6, 23). The hazard
ratios of developing pneumonia, septicemia, or meningitis
have been shown to be 7.7-, 15.6-, and 16.6-fold, respectively,
in patients with MM, compared with population-based age-
matched controls (23).
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The mechanisms of antibody deficiency and hence infection
susceptibility in CLL are multifactorial. Defective function of
the non-clonal CD5-negative B cells and direct suppression
of CD95+ bone marrow plasma cells through CD95L/CD95
interactions between plasma cells and CLL-B cells are postulated
to cause a B cell defect (13). Regulatory abnormalities
in T cells (e.g., decreased helper T cell or increased T
suppressor cell activity) (24) and dysfunctional dendritic cells
or natural killer cells may also contribute to the infection
burden associated with hypogammaglobulinemia in CLL and
MM (2, 6, 13). There is also evidence that CLL-B cells
replace normal B cells (25), thereby inhibiting the function
of non-malignant B cells by subverting T cell help in
the pseudofollicle (26), and may also directly suppress IgG
production by bone marrow plasma cells (27). Additional B cell–
independent risk factors, such as neutropenia, and significant
renal dysfunction can be both disease related and a consequence
of treatment. Furthermore, renal disease can act as a cofactor
in increasing infection burden not only in CLL and MM but
in other settings where there is significant renal impairment
(28, 29).
Therapeutic Agents That Can Cause
Secondary Antibody Deficiency
Although CLL and MM can themselves result in secondary
antibody deficiency, there is also an additional risk of iatrogenic
secondary antibody deficiency posed by the therapies used to
treat these, and other conditions (Table 1). Therapies for CLL and
MM often suppress immune function, increasing the likelihood
of clinically significant infection primarily depending on the
actions of the drug, its dose, the duration of treatment, and the
stage of CLL (123). According to the market research survey
mentioned above, iatrogenic secondary antibody deficiency
accounted for 12.8–22.1% of all secondary antibody deficiency
cases worldwide (20).
Drugs given as chemotherapy include alkylating
agents (cyclophosphamide, chlorambucil, bendamustine),
corticosteroids, and purine analogs (fludarabine, cladribine, and
thiopurines) (6). Treatment with alkylating agents is known to
be associated with the development of myelosuppression, during
which common infections include pneumonia and bacteremia,
caused predominantly by S. aureus, Streptococcus pneumoniae,
H. influenzae, and Klebsiella pneumoniae (6). Purine analogs
and purine synthesis inhibitors (such as mycophenolate
mofetil) inhibit DNA synthesis, thereby reducing T and B
cell proliferation. Use of these therapies, therefore, is more
commonly associated with opportunistic infections (e.g., VZV,
Listeria monocytogenes, and Candida spp.) in patients with
hematological malignancies (6).
It is well-known that high-dose and long-term treatment with
systemic steroids exerts immunosuppressive effects on cellular
immunity; however, there is a growing appreciation of the
impact on antibody production. A study of the prevalence of
hypogammaglobulinemia in 36 patients with giant cell arteritis
and polymyalgia rheumatica on glucocorticoid therapy reported
that approximately half of the patients developed IgG deficiency
with less impact on IgA and IgM and a reduction in naïve B cells
with relative preservation of class switched memory B cells (73).
Importantly, diagnostic findings such as this relatively IgG-
specific effect of glucocorticoid therapy, can be used clinically
to help determine the etiology of antibody deficiency (primary
or secondary), a distinction which is diagnostically challenging
(73). It is particularly difficult to determine causality of
antibody deficiency following administration of therapies known
to potentially cause secondary antibody deficiency, especially
in situations where both the disease and the treatment used can
cause secondary antibody deficiency (e.g., CLL), as well as when
multiple lines of immunosuppressive therapy have been used
over time (5, 73). In the case of heart transplantation, single
center, multi-center, and metanalysis studies have demonstrated
the role of immunological monitoring of humoral immunity
using similar tools and cut-offs as those used in the diagnosis of
PAD (124–126).
There are also diseases other than hematological malignancies
that are associated with an increased risk of secondary antibody
deficiency following treatment. For example, in antineutrophil
cytoplasmic antibody-associated vasculitis (AAV), secondary
antibody deficiency of IgG <4 g/L occurs commonly, presenting
in 9% of patients after rituximab induction and in a further 4.6%
of patients with maintenance therapy in those with low initial
IgG levels (127). This degree of secondary antibody deficiency is
higher than observed for the long-term combination of rituximab
and methotrexate in rheumatoid arthritis, where reduced levels
of IgG, IgA, and IgM were observed in 3.5, 1.1, and 22.4% of
patients, respectively (128). It is of course difficult to determining
whether this increase in the incidence of secondary antibody
deficiency is clearly disease specific, but the findings do suggest
that a high index of suspicion is needed in this condition
in particular.
In neurology, B cell ablation is being increasingly used,
for conditions including neuromyelitis optica spectrum
disorders, relapsing-remitting multiple sclerosis, myasthenia
gravis, autoimmune encephalitis, immune mediated peripheral
neuropathies and primary angiitis of the central nervous system,
with reports of secondary antibody deficiency consequent
upon the use of these agents (129, 130). Clozapine, a
drug used in treatment-resistant schizophrenia, has been
associated with an increased incidence of pneumonia and
death from infection. It has also recently been found
to be associated with secondary antibody deficiency, as
demonstrated by levels of IgG, IgA, and IgM below the
reference range in 8.5%, 13.8%, and 34% of patients,
respectively (70).
Newer Therapeutic Agents That Can Cause
Secondary Antibody Deficiency
While the risk of secondary antibody deficiency in patients
with CLL and MM and those treated with traditional
chemotherapeutic agents has been relatively well-described
in older studies, there have been major therapeutic advances
which have significantly influenced the risk of iatrogenic
secondary antibody deficiency. Amongst these advances, of
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TABLE 1 | Reported outcomes of therapeutic agents with the potential to cause iatrogenic secondary antibody deficiency.
Drug Total number
of patients in
cited studies
Secondary antibody
deficiency
Infection
incidence
Vaccine responses B cell subsets References
Atacicept 697 Decreased IgA, IgG Increased infection
incidence
No effect on tetanus or
diphtheria vaccine
immunization status
Transiently increased mature
and total B cells, followed
by decreased mature and
total B cells. Transiently
increased memory and
naïve B cells
(30–37)
Belimumab 4552 Rare minor
hypogammaglobulinemia
No change in
infection incidence
No effect on
pneumococcal, tetanus
or influenza vaccine
immunization status
Decreased total, transitional,
naïve and activated B cells.
Possibly transiently
increased memory B cells
(38–52)
Bendamustine 396 Hypogammaglobulinemia
(IgG)
Increased infection
incidence
– – (53–55)
Blinatumomab 332 Hypogammaglobulinemia
(predominantly IgA)
Possibly increased
serious infection
incidence
– Decreased total and
peripheral blood cells
(56–61)
Bortezomib 741 Decreased IgG, IgA,
and IgM (but not
hypogammaglobulinemia)
Increased
incidence of HZ
infections and VZV
reactivation
No effect on measles,
mumps or tetanus
vaccine immunization
status
No effect on B cells (62–64)
Chlorambucil 24 Decreased IgM (but not
hypogammaglobulinemia)
No change in
infection incidence
– – (65, 66)
Cladribine 205 No effect on
immunoglobulins
Increased infection
incidence
– Decreased total B cells (67–69)
Clozapine 119 Hypogammaglobulinemia
(IgG, IgA, and IgM)
– – – (70–72)
Corticosteroids 274 Hypogammaglobulinemia Increased infection
incidence
No effect on influenza
vaccine immunization
status
Decreased naïve and
transitional B cells. No effect
on memory B cells
(73–75)
Daratumumab 319 – Increased infection
incidence
– No effect on B cells (76, 77)
Epratuzumab 1468 Decreased IgM (no
effect/possibly
increased IgA or IgG)
– – Decreased total B cells (78–84)
Fludarabine 27 Hypogammaglobulinemia Increased infection
incidence
– – (85)
Ibrutinib 894 Hypogammaglobulinemia
(IgG, IgA, and IgM)
Increased infection
incidence
No effect on influenza
vaccine immunization
status
– (16, 86–91)
Idelalisib 267 No effect on
immunoglobulins
Increased infection
incidence
– – (92–95)
Inebilizumab 51 Decreased IgG, IgE,
IgG, and IgM (but not
hypogammaglobulinemia)
Increased infection
incidence
– Decreased total B cells (96, 97)
Mycophenolate
mofetil
669 Decreased IgG and IgM Increased CMV
and bacterial
infection incidence
Suppressed response to
influenza vaccine
Decreased plasmablasts (98–102)
Ocrelizumab 2830 Hypogammaglobulinemia
reported (mostly IgM)
Increased infection
incidence
No effect on mumps,
rubella, varicella, or
pneumococcal
immunization status
Decreased total and
peripheral B cells
(103–110)
Rituximab 500 Hypogammaglobulinemia
(IgA, IgG, IgM)
Increased infection
incidence
Suppressed response to
pneumococcal and
haemophilus influenzae
immunization status. No
effect on tetanus or
diphtheria immunization
status
Decreased total B cells (17, 111–118)
(Continued)
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TABLE 1 | Continued
Drug Total number
of patients in
cited studies
Secondary antibody
deficiency
Infection
incidence
Vaccine responses B cell subsets References
Rozanolixizumab 36 Decreased IgG (no
effect on IgA, IgD, IgE
or IgM)
No change in
infection incidence
No effect on tetanus or
influenza immunization
status
No effect on B cells (7)
Thiopurines 102 Decreased IgA, IgG,
and IgM
No change in
infection incidence
No effect on
pneumococcal, tetanus
or haemophilus
influenzae type B
vaccine immunization
status
– (119–122)
particular relevance are the many new B cell targets shown
in Figure 2 (2, 6). These treatments either deplete B cells
(anti-CD20, anti-CD52, anti-CD74, anti CD19, anti-CD22)
and plasma cells (anti-CD38) or inhibit B cell survival (anti-B-
cell activating factor [BAFF]), impair activation (proteasome
inhibitors, tyrosine kinase inhibitors) or interaction with T
cells (anti-CD80/86) (2) and all have the potential to cause
iatrogenic secondary antibody deficiency. Bruton’s tyrosine
kinase (BTK) inhibitors, such as ibrutinib, target BTK to inhibit
B cell survival and proliferation (Figure 2), and are increasingly
used in CLL (16, 131, 132), with severe infections of Grade 3 or
higher reported in up to 35% of patients (132). Blinatumomab,
a bispecific T cell engager (BiTE) antibody, crosslinks CD3
on T cells to CD19 on B cells activating endogenous T cells
to proliferate and become cytotoxic to CD19-positive B cell
targets (133) and, as such, is also expected to have the potential
to cause secondary antibody deficiency. The phosphoinositide
3-kinase δ inhibitor idelalisib, approved for the treatment of
CLL, follicular lymphoma, and small lymphocytic lymphoma,
has been associated with increased risk of infections, including
pneumonia (92). In addition to these, there is a rapidly increasing
number of other new anti-B cell agents, including those targeting
molecules expressed by B cells throughout different parts of
their developmental pathway such as CD19, CD20 CD22, CD38,
CD74, and proteasomes (Figure 2) (38, 96, 134–148).
Given the relatively recent development of some of these
therapies, evidence for secondary antibody deficiency during
their use is limited by study size, disease setting, and duration
of therapy.
In the case of anti-CD19 agents, reductions in all
immunoglobulin classes have been reported (although still falling
within the reference range) during a small study of inebilizumab
in multiple sclerosis (96) and hypogammaglobulinemia was
reported in 6% of patients treated with blinatumomab (149).
There is more limited information on the incidence of secondary
antibody deficiency for the anti-CD20 antibodies ofatumumab
and ocrelizumab, however an increase in infection incidence has
reported for ocrelizumab (150).
Results thus far have shown a reduction in IgM but not
IgG for the anti-CD22 antibody epratuzumab (78), and a
potential increase in the incidence of VZV infection with
the anti-CD38 agent daratumumab which targets plasma cells
(151). The proteasome inhibitor bortezomib has been associated
with increased incidence of VZV infection, in addition to
herpes simplex virus infection (29). For the anti-CD74 agent
milatuzumab, currently in development, there are as yet no
published data related to secondary antibody deficiency or risk
of infection, and for all of these more recently-developed agents,
longer-term studies will be needed to define the degree of impact
on immunoglobulins in different disease settings.
Interestingly, anti-BAFF therapy with belimumab has not
been associated with a reduction in IgG, pneumococcal
antibodies or an increase in infection, and IgM memory B
cells have been shown to be reduced while class switched
memory B cells were preserved (38, 39). For the transmembrane
activator and calcium-modulating cyclophilin ligand interactor-
Ig fusion protein atacicept, used in systemic lupus erythematous
and rheumatoid arthritis, a reduction in all immunoglobulins
has been reported, although this was not linked to infection
(152–154).
A good example of increased potency of some of the new
therapies are chimeric antigen receptor (CAR)-T cells with
synthetic, engineered receptors targeting B cells (e.g., anti-CD19)
which are used for the treatment of hematological malignancies
(155–157). These engineered T cells can proliferate and retain
effector functions of the activated T cells. The likelihood of
iatrogenic secondary antibody deficiency with CAR-T therapy is
so high that B cell depletion is acknowledged as an “expected
on-target result” which may require the use of IgRT (155).
Future Therapeutic Agents That Could
Cause Iatrogenic Secondary Antibody
Deficiency
Novel therapeutic strategies continue to be identified. The
tetravalent bispecific anti-CD19/CD3T and Ab tandem diabody
AFM11, which consists only of Fv domains, with two binding
sites for CD19 on B cells and two for CD3 on T cells, was
designed to exhibit higher potency than blinatumomab owing
to the bivalent binding of the Fv domains to both B and T
cells, resulting in enhanced B cell lysis (158). These immune
cell-recruiting bispecific antibodies harness the cytotoxic potency
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of endogenous T cells (or in some cases NK cells) to kill both
malignant and normal B cells (158).
Yet other treatments are becoming available that may be able
to treat their target diseases not by interfering with antibody
production but by removing pathogenic autoantibodies by
reduction of their half-life. Rozanolixizumab, for example, is an
anti- FcRn monoclonal antibody (Figure 2) (7). FcRn salvages
and recycles plasma IgG autoantibodies, thus extending their
lifespan (7, 159). Selective inhibition of FcRn, and hence the
salvage pathway, offers a new approach for the removal of
pathogenic IgG autoantibodies in the treatment of autoantibody-
mediated disease. While pre-clinical and clinical studies of
rozanolixizumab have not shown an increase in the incidence
of infection (7), long-term studies and close monitoring will be
needed. As mentioned above, the risk of infection appears lower
where there is removal (plasma exchange, anti-FcRnmAb) or loss
(protein-losing enteropathy or renal loss) of functionally normal
antibody rather than a production failure. This may translate into
a lower infection risk with anti-FcRn therapies; however, long-
term data will be required and it would seem prudent to optimize
protection from infection by ensuring appropriate vaccination
prior to commencement of therapy.
Solid Organ Transplantation (SOT)
In addition to the risks associated with hematological malignancy
and immunosuppressive drugs, there are also other, perhaps
less well-recognized situations in which patients are at risk
of developing secondary antibody deficiency. Solid organ
transplantations (SOTs) are now routine surgical procedures
for treating organ dysfunction, with an estimated 119,873 SOTs
performed worldwide in 2014, and 30,970 in the US alone in
2015 (160). Patients receiving SOT are given immunosuppressive
drugs before, during, and after transplantation to prevent organ
rejection (161). While immunosuppressive drugs are recognized
as a common cause of secondary antibody deficiency, there are
additional risks in SOT including the transplantation procedures
themselves as well as other interventions, such as the use of
ventricular assist devices in heart recipients or extracorporeal
membrane oxygenation in heart and lung recipients, which are
also associated with the occurrence of SOT-related secondary
antibody deficiency (162, 163). Several studies have shown
a high prevalence of hypogammaglobulinemia after SOT,
particularly after heart, lung, and kidney transplantation, with
an associated increased risk for infections (124, 164). Infections,
most frequently non-CMV infections, are reported to be the
leading cause of death during the first year after heart or lung
transplantation (Figure 3) (163). In one meta-analysis of 669
SOT patients, 15% developed severe hypogammaglobulinemia
(IgG < 4 g/L) during their first year post transplantation
(124). This study also reported a 4.8-fold increase in respiratory
infections, a 2.4-fold increase in CMV infections, and an 8-
fold increase in aspergillus infections (3.7-fold increase in
other fungal infections) when severe hypogammaglobulinemia
was present (124). Furthermore, two other groups have also
reported an increased incidence of opportunistic infections in
heart transplantation with hypogammaglobulinemia, particularly
FIGURE 3 | Relative incidence of leading causes of death (31 days to 1 year)
in adults receiving heart transplants Jan 1994–June 2016. Developed using
data from The International Society for Heart & Lung Transplantation, (2017)
(163); CMV, cytomegalovirus.
CMV viremia (126, 162). In addition, lower levels of anti-
pneumococcal antibodies are a risk factor for development of
severe bacterial infections in heart recipients (165).
DIAGNOSIS
The prompt diagnosis of secondary antibody deficiency is key
in reducing infection burden and is dependent on appropriate
screening and an appreciation of risk factors for secondary
antibody deficiency development. Monitoring of patients at
risk of developing secondary antibody deficiency, such as
patients receiving conventional immunosuppressive drugs or
newer, more targeted therapies, could help in identifying these
patients before they develop a serious infection. For rituximab,
which is known to be associated with the development of
secondary antibody deficiency, the risks for an individual are
increased with low baseline IgG prior to rituximab initiation;
exposure to prior therapies, such as cyclophosphamide, steroids,
and purine analogs, purine synthesis inhibitors (mycophenolate
mofetil), or the use of combination therapy or granulocyte-
colony stimulating factor (166). Furthermore, the single use
of rituximab rarely causes hypogammaglobulinemia, yet there
is an increased risk for patients undergoing maintenance
or multiple cycles of treatment. Finally, patients with co-
morbidities, such as chronic lung or heart disease and
extra-articular rheumatoid arthritis, have higher instances of
hypogammaglobulinemia, with more infections occurring when
IgG is low for longer than 6 months (166). Although there
may also be particular non-hematological diseases which
have higher rates of secondary antibody deficiency, such as
AAV and neuromyelitis optica spectrum disease, the caveat
remains that it is difficult to separate the effect of treatment
from disease.
The evaluation of patients at high risk or with suspected
hypogammaglobulinemia should include quantitative serum Ig
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concentrations and analysis of vaccination responses if initial
specific antibody levels are found to be low. High-risk patients
may merit annual immunoglobulin measurements to screen for
the development of secondary antibody deficiency. It is likely
that in some cases it will be helpful to determine levels and
reconstitution of B cell numbers, including the preservation of
class-switched memory B cell and plasma cell compartments.
For example, in some settings the measurement of the return
of class-switched memory B cells is already being used to
determine the timing of retreatment with rituximab to reduce
the cumulative rituximab dose without apparent loss of efficacy
(167). In addition, complete blood count will assist in identifying
additional risk factors such as neutropenia, lymphopenia, or
lymphocytosis (2, 168).
Some treatment-specific screening or monitoring programs
have been introduced to mitigate infection-related risk; for
example, the Pharmacovigilance Risk Assessment Committee of
the EMA recommends that patients receiving idelalisib should
be informed about the risk of serious and/or fatal infections,
given prophylaxis for Pneumocystis jirovecii pneumonia, and
monitored for signs and symptoms of respiratory infections
throughout the idelalisib treatment. Regular clinical and
laboratory screening for CMV infection should also be conducted
and absolute neutrophil counts monitored in all patients at least
every 2 weeks for the first 6 months of treatment. In the case of
clozapine, the Clozapine Risk Evaluation and Mitigation Strategy
(REMS) monitoring scheme has been established to reduce the
risks associated with neutropenia, however antibody monitoring
is not currently part of the scheme (169).
In patients receiving SOT, several biomarkers have been
shown to be useful in stratifying the risk of developing SOT-
related secondary antibody deficiency and associated infections.
For example, in patients receiving a heart transplantation,
IgG levels of <10 g/L prior to transplantation may predict
high frequency of bacterial infections, therefore suggesting
that monitoring of IgG levels prior to transplantation may be
important in predicting secondary antibody deficiency and
subsequent infection. Similarly, low levels of class-switched
memory B cells may also act as pre-heart transplantation
biomarkers. Several post-heart transplantation biomarkers, such
as low peripheral lymphocyte populations, may also help in
predicting infections. For example, low anti-CD8 response to
CMV antigens assessed by enzyme-linked immune absorbent
spot (ELISPOT) or flow cytometry can be used as a biomarker
for the risk of developing CMV infection and disease (170).
Other prospective post-SOT biomarkers include complement
components (e.g., C3 and C4), owing to their effector functions
in the innate and adaptive humoral immune responses (171). The
classic in vitro hemolytic assays utilized for assessing classical
and alternative complement pathway function are complex,
susceptible to pre-analytical sample handling issues, and time
consuming. Nephelometry represents a convenient option for
the measurement of certain complement components in serum
(172). As complement activation is responsible for the clearance
of encapsulated bacteria, hypocomplementemia may result in
increased susceptibility to infection (171). It has been shown that
hypocomplementemia is an indicator of bacterial infection risk
in patients following kidney transplantation (173), with similar
findings reported for liver (174) and heart (175) recipients. The
combination of low IgG and low C3 in serum can be particularly
detrimental in SOT patients. One multivariate analysis
demonstrated that hypogammaglobulinemia (IgG <6 g/L)
or C3 hypocomplementemia (C3 <80 mg/dL) on Day 7 post
heart transplantation were independent risk factors for infection
(especially bacterial infections) andCMVdisease (125). However,
the combination of both was more strongly associated with the
risk of infections than either hypogammaglobulinemia or C3
hypocomplementemia alone. Furthermore, on Day 7, low anti-
CMV antibody titers and low anti-pneumococcal polysaccharide
antibody concentrations as biomarkers of impaired specific
antibody responses were independent predictors of CMV disease
and bacterial infections, respectively (125). These biomarkers
can be used to identify patients at high risk who may benefit
from IgRT post heart transplantation (Table 2, Figure 4). The
evaluation of CMV IgG serology of donor and recipient is a
classic evaluation to identify the risk of CMV disease after SOT
(170). CMV seronegative recipients receiving an allograft from a
CMV seropositive donor are considered to be at higher risk of
having this complication than other serological combinations.
More recently, the assessment of CD8 responses to CMV
antigens has also been introduced to evaluate the risk of CMV
disease in SOT (170).
An interesting aspect of the management of heart and other
SOT recipients is that vaccination is not common practice during
the first months after transplantation, when themajority of severe
infections occur, because the specific antibody response after
immunization in this period has been demonstrated to be low
(187). This should be taken into account at the time of diagnosing
secondary antibody deficiency in this setting. Moreover, the
titers of anti-pneumococcal or anti-CMV antibodies gradually
decline during the first year after transplantation as a result of
the immunosuppressive therapy, leaving the patients exposed to
infection (165, 178, 188).
TREATMENT
While removal of the underlying causative factor would
be the preferred option for treating secondary antibody
deficiency, (e.g., as a consequence of the removal of an
abnormal section of bowel in protein-losing enteropathies
or reduction of immunosuppression post hematopoietic stem
cell transplantation [HSCT]) this is overall rarely possible,
particularly when treatment cannot be easily avoided as is
the case with SOT, CLL, MM, or lymphoma. Indeed, in the
case of HSCT, this may also itself lead to secondary antibody
deficiency and subsequent infection, the risks of which are
increased by the presence of graft vs. host disease (GvHD)
in these patients (189, 190). While the mechanism of GvHD-
mediated secondary antibody deficiency is not fully understood,
it is thought to potentially delay B cell engraftment, leading
to B cell lymphopenia, and to delay/prevent B cell maturation
and memory development, markedly decreasing memory and
switched memory B cells (191, 192).
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FIGURE 4 | A combined immunodeficiency profile identifies risk of severe infection in heart transplant recipients. Developed using data from Sarmiento et al. (186). C,
complement; CD, cluster of differentiation; CMV, cytomegalovirus; IVIG, intravenous immunoglobulin; NK, natural killer.
In hematological malignancy, supportive treatments
including prophylactic vaccination (with non-live vaccines),
antibiotics and/or IgRT may be considered for patients with
secondary antibody deficiency. A careful review of the patient’s
history, assessment of the risk factors for developing secondary
antibody deficiency and evaluation of serum IgG levels and
specific antibody levels is key to the diagnosis and treatment.
Immunologists often have greater experience in managing PAD
than secondary antibody deficiency, and it is likely that the
clinical and laboratory assessments used in this setting would
also be of utility in secondary antibody deficiency. However,
there is limited evidence in the literature, particularly relating
to the increasing number of newer therapies, to guide clinical
management of secondary antibody deficiency.
Prophylactic Vaccination
Prophylactic non-live vaccinations such as influenza are
recommended for patients with secondary antibody deficiency,
as is the case in PAD. Although the antibody response may
not be optimal, some helpful protection via antibodies and T
cell immunity may still be achieved; thus, influenza vaccination
is advised. Live vaccination is generally not recommended in
patients with secondary antibody deficiency (although individual
assessment and decisions are warranted). Instead, component
or inactivated vaccines should be used. Studies suggest that
vaccination at an early stage (before initiation of chemotherapy
and the onset of hypogammaglobulinemia) may be more helpful
in generating immunological memory when specific antibody
levels are low (123). In addition, evaluation of post-vaccination–
specific antibody levels can be beneficial both therapeutically (if
protective levels are achieved) and in stratification of risk before
and following treatment. Vaccination against S. pneumoniae and
H. influenza is recommended in patients with CLL; however, the
protective effect of these vaccines may be variable, emphasizing
the importance of ongoing immunological assessment and
individualization of care (6). In a UK-based study of patients
with MM, 61% (26/43) showed a suboptimal response to
S. pneumoniae vaccination, whereas 75% (33/46) showed a
response to H. influenzae type B vaccination comparable with
those in the healthy adult UK population. The European
Myeloma Network guidelines (193) suggest that “vaccination
against influenza virus is appropriate and is recommended
for both patients and their contacts. Moreover, vaccination
against Streptococcus pneumoniae and Haemophilus influenzae
is recommended, but efficacy for all vaccines is not guaranteed,
due to suboptimal immune response (grade 1C). In general,
live vaccines should be avoided in myeloma patients (grade
2C)” (193).
The Infectious Diseases Society of America has recommended
the routine use of inactivated vaccines in patients with MM
unless they are actively receiving chemotherapy or monoclonal
antibody (194). The Advisory Committee for Immunization
Practices recommends that patients with MM and SOT should
receive vaccination with pneumococcal conjugate vaccine at
diagnosis followed by revaccination more than 8 weeks later
(195). Recent MM guidelines from the National Comprehensive
Cancer Network do not include specific recommendations for
vaccination, but do note to “consider Pneumovax and influenza
vaccine” (196).
In terms of pre-transplantation vaccination schedules, it
is suggested that primary immunizations should be given
as soon as possible before transplantation (197). Data from
a study of pediatric patients showed that vaccination prior
to transplantation was effective in reducing the incidence of
Varicella Zoster virus infection from 45–12% (198). Guidelines
for vaccination of SOT recipients recommend vaccination against
S. pneumoniae and H. influenzae before transplantation (197,
199). As mentioned, post-transplantation, anti-pneumococcal
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TABLE 2 | Biomarkers used following heart transplantation.
Organ Biomarker
(post HT)
Outcome References
Heart IgG <3.5 g/L Opportunistic infection (162)
Heart IgG <3.1 g/L Opportunistic infection (176)
Heart IgG <6 g/L Bacterial, CMV
infection
(126)
Heart IgG <7 g/L Bacterial, CMV
infection
(165)
Heart IgG <4 g/L Clostridium difficile (177)
Heart IgG <5 g/L CMV disease (178)
Heart Low IgG2 Overall infection (175)
Heart anti-PPS <5
mg/dL
Bacterial infection (165)
Paed heart Low anti-PPS Not done (179, 180)
Heart Low anti-CMV
titres
CMV infection (178, 181, 182)
Heart C3 <80 mg/dL Overall infection (183) First
proposal of an
immunological
score
Heart NK <30
cells/uL
Heart CD4 <350
cells/uL
Heart Low anti-CD8
response to
CMV
CMV infection (183–185)
C3, complement component 3; CD, cluster of differentiation; CMV, cytomegalovirus;
HT, heart transplant; IgG, immunoglobulin; NK, natural killer; PPS, pneumococcal
polysaccharide.
antibody titers have been shown to significantly decrease in
kidney (188) and lung transplant recipients (200). Questions
remain regarding the utility and timing of vaccination in
secondary antibody deficiency and further studies are needed (6).
While it is generally accepted that inactivated vaccines can
be administered in patients with secondary antibody deficiency,
many vaccinations are not required for those patients receiving
IgRT, as protective levels of antibodies are already present in the
IgRT preparations and should offer some protection against a
range of infectious diseases (201, 202). Influenza vaccination is an
exception, as these vaccines are reformulated annually to reflect
changes in the antigenic composition of the influenza virus and
protection from IgRT is therefore less likely. However, even if
the antibody response post vaccination is suboptimal, patients
with PAD and also secondary antibody deficiency may benefit
from the T cell-mediated responses (112, 203). Live vaccines
are generally not recommended in the context of significant
immunodeficiency and in patients receiving IgRTmay also be less
effective (204).
Prophylactic Antibiotics
Treatment of secondary antibody deficiency with prophylactic
antibiotics is the recommended first-line therapy in CLL (205)
and during periods of neutropenia in patients undergoing
chemotherapy or other immunocompromising treatments (11).
Antibiotic therapy should take into account the previous culture
and sensitivity results as well as any allergies, tolerance, and the
likelihood of Pseudomonas or macrolide-resistant H. influenzae
infection. In the event of a breakthrough infection, if there has
been no or limited response to a back-up course of antibiotics
and a second course of different antibiotics, then intravenous
antibiotic (IVAB) treatment should be considered. Prophylactic
and back-up antibiotics should be of different classes (e.g.,
macrolide and penicillin class), rather than simply increasing
the dose of the existing prophylactic regimen. Monitoring (e.g.,
electrocardiogram) and additional patient information (e.g.,
regarding the development of tinnitus) may be needed for those
on long-term macrolides. There are many potential antibiotic
options and the examples shown in Table 3 are illustrative, with
individual decisions being made on clinical grounds and local
prescribing policy. Nebulized antibiotics and intermittent IVAB
are options that are used mainly for severe bronchiectasis and
pseudomonal colonization (Table 3).
Current Use of IgG
Many studies have demonstrated decreased infection incidence
in patients with CLL treated with intravenous IgG (IVIG;
Table 4). The beneficial effect of IVIG was demonstrated in
a randomized, controlled, double-blind clinical trial conducted
by the Cooperative Group for the Study of Immunoglobulin,
where use of IVIG was associated with lower incidence of
bacterial infections and longer time during which patients were
free of serious bacterial infections compared with patients not
receiving IVIG (206). A subsequent double-blind crossover
follow-up study confirmed that maintenance on IgG results
in reduction of the infection incidence (210). Later, another
double-blind crossover study compared two doses of IVIG
(250 and 500 mg/kg) over a year, suggesting a significant
difference in the incidence of bacterial infections between
doses (208). These promising results prompted a consensus
statement supporting the use of IVIG in patients with CLL
with hypogammaglobulinemia and associated infections (213).
However, as these studies are well over a decade old, there is a
clear need for newer randomized trials in this area, particularly
given the vast advances in treatment and improved survival.
Protocols for IgRT in secondary antibody deficiency vary. In
clinics based in Oxford and Cardiff, UK, very similar approaches
are employed where the use of IgRT and the dose administered
are individualized per patient (5). In patients referred to the
immunology department for recurrent and/or serious bacterial
infections, immunization responses are measured 4–6 weeks
after administration of protein and polysaccharide vaccines (if
initial levels are low) and during the waiting period, for up
to 3 months, prophylactic antibiotic use is considered. A 12-
month trial of IgRT (with infection monitoring) is considered
in case of antibody failure and a lack of an adequate response to
prophylactic antibiotics in association with a significant ongoing
infection burden. Neutrophil count, serum IgG trough levels,
and infection burden should be monitored regularly, and IgG
use, including dosage, should be reviewed after 6 and 12 months
to maintain plasma IgG trough levels sufficient for an optimal
reduction in infection rate. Levels of IgG should be reviewed if
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TABLE 3 | Graded antibiotic regimens*.
Antibiotic
regimen
Dosing schedule Additional options Emergency plan Example
Intermittent
antibiotics
None Attend GP with symptoms N/A
None Early use of home back-up
antibiotics
Co-amoxyclav 625mg tds for 2
weeks; held at home
Prophylactic antibiotics
during the winter
months with home
rescue during the
summer
Low-dose and full-dose options,
e.g., azithromycin 250 or 500mg
3 days/week
Early use of home back-up
antibiotics
Azithromycin 500mg 3 days/week
plus back-up Co-amoxyclav for 2
weeks; held at home
Ongoing
prophylaxis
Prophylactic antibiotics Low-dose and full-dose options,
e.g., azithromycin 250 or 500mg
3 days/week
Early use of home back-up
antibiotics
Azithromycin 500mg 3 days/week
plus back-up Co-amoxyclav 625mg
tds for 2 weeks; held at home
Rotating prophylactic
antibiotics
Early use of home back-up
antibiotics
Prophylactic antibiotics Nebulized antibiotics Early use of home back-up
antibiotics
Nebulized Colomycin 1–2 mega units
bd
Prophylactic antibiotics Intermittent planned IVAB Early use of home back-up
antibiotics
Meropenem 2g IV tds and
Ceftazidime Co-amoxyclav for 2
weeks; held at home
GP, general practitioner; IV, intravenous; IVAB, intravenous antibiotic; N/A, not available; bd, twice daily; tds, three times daily.
*If there has been an inadequate response to back-up antibiotics and an additional antibiotic in another class then intravenous antibiotics (IVAB) should be considered. The Table shows
examples of antibiotic regimens and the antibiotic choice will depend on individual clinical circumstances.
TABLE 4 | Summary of evidence for the use of immunoglobulin replacement therapy in CLL.
Reference Number of
patients
Number of patients
in advanced stage*
Type of study Dose
IVIG/schedule
Study duration
(months)
Infection rate during
IVIG administration
Cooperative group
(206)
81 32 (39.5%) Controlled, randomized
double-blind
400 mg/kg/ 21
days
12 Decreased
Jurlander et al.
(207)
15 8 (53.3%) Not controlled, pilot 10 g/28 days 12 (mean time) Decreased
Chapel et al. (208) 34 15 (44.1%) Controlled, randomized
double-blind
250 mg/kg vs. 500
mg/kg/28 days
12 Decreased
Sklenar et al. (209) 31 2 (6.4%) Dose-finding 100–800 mg/kg/
21 days
4.5 Decreased
Griffiths et al. (210) 10 3 (30%) Controlled, randomized
double-blind
400 mg/kg 21
days
12 Decreased
Broughton et al.
(211)
42 15 (35.7%) Randomized 18 g/21 days 12 Decreased
Molica et al. (212) 30 25 (83.3%) Randomized, crossover 300 mg/kg/28
days
6 or 12 Decreased
*Binet stage C or Rai III-IV.
chemotherapy is introduced during IgRT. Because patients react
differently to IgRT, individualization of the treatment regimen is
required (5).
One of the key factors to consider when initiating IgRT is
selection of patients most likely to benefit (Figure 5). Studies
suggest that patients with IgG levels <4 g/L and/or low levels
of antibodies against encapsulated organisms with an ongoing
history of recurrent bacterial infections that have not responded
adequately to prophylactic antibiotics could especially benefit
from IVIG (211, 215). Furthermore, selection of the patients
should include a wider assessment of comorbidities and innate
immunological abnormalities, such as neutropenia, as well as
demonstrating antibody failure (exposure/test immunization).
If IgRT is to be administered, a careful risk-benefit assessment
should be made. This should take into consideration, for
example, the reported adverse effects of IgRT, such as the rare
complications of thromboembolism and hemolysis in patients
with hematological malignancies (216, 217). Once it is established
that IgRT should be offered to a patient with secondary antibody
deficiency, the route [subcutaneous IgG [SCIG] or IVIG] and
location (home vs. clinic) of infusions should be considered.
SCIG has similar efficacy to IVIG (218, 219) but offers several
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potential benefits, including more stable serum IgG levels (219,
220), improved patient health-related quality of life (221), and
time and cost efficiencies for both patients and healthcare
providers. It has also previously been shown that the feasibility
and safety of home IVIG therapy in selected CLL patients may
improve patient compliance and considerably decrease costs
(222). It is also recommended that patients complete at least
12 months (encompassing all 4 seasons) of IgRT in order to
optimally assess the response to therapy (11). This will require
ongoing review to reflect any clinical changes in the patient’s
underlying condition and therapy. Treatment discontinuation
may be considered in stable patients with reduced incidence
of infections (i.e., once treatment has restored function) to
determine if IgRT is still required, or in patients where treatment
does not seem to be effective in preventing infection (i.e.,
treatment failure) (11).
Prophylactic use of IgRT in patients post SOT has
been shown to decrease the incidence of severe infection
in patients with hypogammaglobulinemia (162, 223). It
has also been shown to decrease the incidence of CMV
infection in patients with hypogammaglobulinemia (224).
Retrospective studies have demonstrated that addition of
IVIG to antimicrobial therapy in heart transplantation
recipients with secondary antibody deficiency and severe
infections is associated with reconstitution of specific antibodies
(anti-CMV, anti-tetanus toxoid) and lower rates of death
(183, 225). A case series performed in heart transplantation
recipients with difficult-to-control CMV infection in whom
secondary antibody deficiency was found demonstrated that
IVIG was associated with reduction in detectable CMV
viremia and with remission of clinical symptoms of CMV
disease (226).
CURRENT EVIDENCE-BASED GUIDELINES
FOR IGRT IN SECONDARY ANTIBODY
DEFICIENCY
The majority of guidelines recommend prophylactic antibiotics
as first-line therapy for patients with CLL susceptible to
serious infections (2). However, an individualized dose and
duration of IgRT is also suggested where there is lack of
responsiveness or failure of the antibiotics to sufficiently reduce
the infection burden in such patients. Looking at specific
recommendations, according to European Medicines Agency
(EMA) 2018 (valid from January 2019); IVIG can be used in
patients with secondary immunodeficiencies “who suffer from
severe or recurrent infections, ineffective antimicrobial treatment
and either proven specific antibody failure (PSAF) or serum IgG
level of <4 g/l,” where PSAF is defined as “failure to mount at least
a 2-fold rise in IgG antibody titer to pneumococcal polysaccharide
and polypeptide antigen vaccines” (214). The dose required is
stated to be probably patient dependent, but is likely to be 0.2–
0.4 g/kg every 3–4 weeks (214). With regard to SCIG, EMA
guidelines state that it is indicated in hypogammaglobulinemia
and recurrent bacterial infections in patients with MM and
in patients with CLL in whom prophylactic antibiotics have
failed or are contraindicated (227). SCIG is also indicated for
hypogammaglobulinemia in patients pre- and post-allogeneic
HSCT. However, the EMA states that “the above indications
would be granted as long as efficacy has been proven in primary
immunodeficiency syndromes” (227).
The European Society for Medical Oncology (ESMO)
guidelines, published in 2015 (228), state that “the use of
prophylactic systemic IgG [in patients with CLL] does not
have an impact on overall survival and is only recommended
in patients with severe hypogammaglobulinemia and repeated
infections [Level of evidence I, A].” They also state that “Antibiotic
and antiviral prophylaxis should be used in patients with
recurrent infections and/or very high risk of developing infections
(e.g., pneumocystis prophylaxis with co-trimoxazole during
treatment with chemoimmunotherapies based on purine analogs
or bendamustine) [IV, B]” and finally, that “pneumococcal
vaccination as well as seasonal influenza vaccination is
recommended in early-stage CLL [IV, B]” (228).
According to The British Committee for Standards in
Hematology, 2012 (205), ” in the absence of recent randomized
studies, recommendations for the use of immunoglobulin
replacement in CLL are largely based on clinical experience
and data from use in primary immunodeficiencies.” Their
recommended indication for the use of IgRT is “recurrent/severe
infection with encapsulated bacteria despite prophylactic oral
antibiotic therapy in patients with a serum IgG <5 g/L (excluding
paraprotein)” (205).
Guidelines published in 2011 by the UKDepartment of Health
(229) recommend that “Immunoglobulin replacement therapy is
recommended in secondary antibody deficiency if the underlying
cause of hypogammaglobulinaemia cannot be reversed or reversal
is contraindicated, or is associated with B-cell malignancy where
severe infections with encapsulated bacteria are persistent despite
prophylactic antibiotic therapy (grade C recommendation, level III
evidence)” (229).
The Criteria for Clinical Use of Immunoglobulin from the
National Blood Authority in Australia provide a variety of
recommendations for IgRT, including: “Prevention of recurrent
bacterial infections due to hypogammaglobulinaemia associated
with hematological malignancies or post haemopoietic stem
cell transplant” (230), and “replacement therapy for recurrent
or severe bacterial infections or disseminated enterovirus
infection associated with hypogammaglobulinaemia caused by
a recognized disease process or B cell depletion therapy and/or
immunosuppressant therapy” (231). Finally, in Canada, guidelines
published in 2018 state that “Immunoglobulin replacement is
recommended for preventing recurrent, severe infection due
to hypogammaglobulinemia (excluding paraprotein) related to
other diseases or medical therapy” (232). Specifically, secondary
antibody deficiency is defined as “Hypogammaglobulinemia
secondary to underlying disease or medical therapy (including
HSCT) with all of the following: Serum IgG less than the lower
limit of the reference range on two separate occasions AND at
least one of the following: a) one invasive or life-threatening
bacterial infection (e.g., pneumonia, meningitis, sepsis) in
the previous year; b) recurrent, severe bacterial infections; c)
Clinically active bronchiectasis confirmed by radiology or d)
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FIGURE 5 | Suggested protocol for the investigation, monitoring, and management of secondary antibody deficiency. Reproduced with the permission of the
copyright holder John Wiley & Sons Inc (5). *See (57, 58, 214);
†
Only >6 month after solid organ transplant. CSMB, class-switched memory B cells; IgA,
immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; SOT, solid organ transplant.
assessment by a physician specializing in immunodeficiency
indicating a significant antibody defect that would benefit from
immunoglobulin replacement” (232).
In the field of SOT, there are currently no published
guidelines regarding the use of IgRT in patients with recurrent
bacterial infections and hypogammaglobulinemia. In the updated
International Consensus Guidelines on the management of CMV
in SOT, published by the Transplantation Society International
CMV Consensus Group, there is a recommendation that,
when CMV disease is difficult to control, IgG testing is
advisable (170). According to expert opinion, CMV-specific
IgRT is recommended for prophylaxis of CMV disease in
high risk CMV seronegative recipients in specific settings,
such as thoracic, intestinal, and pediatric transplantation (170).
The European Society of Clinical Microbiology and Infectious
Diseases guidelines recommend antiviral prophylaxis treatment
for patients at high risk of CMV disease, such as lung and
intestinal transplant recipients (233).
Overall, most guidelines are in support of considering IgRT
initiation in selected patients with secondary antibody deficiency.
In patients with risk factors (e.g., cardiovascular disease,
diabetes, renal impairment, and thrombosis risk), a careful risk-
benefit assessment should determine whether initiating IgRT is
advisable. Also, the dose, route, and administration frequency
should be optimized for each patient individually to maintain
acceptable plasma IgG levels and a substantial reduction of
infection rates (234). However, further clinical studies are
required to improve and/or validate our current practice in
prescribing IgG to patients with secondary antibody deficiency
especially given the growth in newer therapies. It is also clear
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that individual assessment remains paramount, as diagnostic
testing remains imperfect and not all patients will fit neatly
into guidelines.
FUTURE DIRECTIONS
As the number and variety of immunosuppressive therapies
increases, so will the incidence of secondary antibody deficiency
(5). Accordingly, the EMA are currently in the process of
updating their guidelines on the use of IVIG to specifically
address secondary antibody deficiency, recommending its use for
“secondary immunodeficiencies in patients who suffer from severe
or recurrent bacterial infections, ineffective antibiotic treatment
and either proven specific antibody failure (failure tomount at least
a 2-fold rise in IgG antibody titer to pneumococcal polysaccharide
and polypeptide antigen vaccines) or serum IgG level of <4
g/L” (235). Their recommended dose is 0.2–0.4 g/kg every 3
to 4 weeks. Indeed, there is also increasing evidence that SCIG
offers an efficacious and efficient treatment option for secondary
antibody deficiency (236).
It should be emphasized that currently, evidence regarding the
newer agents is limited by study size, duration, and the number
of disease settings, and longer-term prospective follow-up studies
will be needed to clearly define the long term cumulative effect on
antibody production and thus inform future guidelines.
In PAD, there are screening and treatment guidelines and
protocols in place to identify and treat hypogammaglobulinemia
(237–239). However, even in these newer, updated guidelines,
there remains a paucity of recommendations related to the
diagnosis and screening for secondary antibody deficiency
or those addressing the treatment of secondary antibody
deficiency specifically. As discussed above, vaccine-specific
antibody response is a key tool in the diagnosis of secondary
antibody deficiency that will benefit from new assays to assess
responses to polysaccharide vaccination, such as Typhim Vi
(typhoid polysaccharide vaccine, Sanofi Pasteur, UK), which
are being increasingly introduced (240, 241). It will also be
important to harness pharmacogenetics in patient selection and
risk stratification. Future guidelines will need to focus on these
under-represented and rapidly growing patient populations to
harmonize and optimize screening, diagnostic, monitoring, and
management approaches.
Avoiding the Consequences of
Hypogammaglobulinemia
Ongoing advances in testing, earlier screening, reducing
diagnostic delay, and optimizing treatment regimens are all ways
to reduce the burden of secondary antibody deficiency.
Determining the concentration of the serum globulin
fraction (calculated globulin), of which immunoglobulins
are a major component, is a useful tool for identifying
undiagnosed patients with secondary antibody deficiency
(242, 243). However, given the variety of causes and settings
in which secondary antibody deficiency may present, raising
awareness of conditions, and treatments that increase the
risk of secondary antibody deficiency is also vital (Figure 5).
The identification of biomarkers, such as those following
heart transplantation (e.g., low anti-CD8 response to CMV,
reduced complement components), will help to stratify
patients by risk and improve recognition. In a wider
context, clinical biomarkers that may assist in patient
identification may include infection burden (particularly
sinopulmonary infection), chronic sinusitis, chronic daily
sputum production suggestive of bronchiectasis (5), or IgG
level (<4 g/L). With regard to infection burden, factors such
as infection frequency, duration, severity, and site should
be considered, along with rates of antibiotic (particularly
intravenous) use and hospitalization. Alongside vaccine
responses, it is advisable to consider other factors, such as
neutropenia, significant renal impairment, multiple lines of
treatments, and ongoing therapy requirement and timing
of vaccination (e.g., in relation to HSCT). In addition,
performing measurements of potential biomarkers at baseline
will enable objective measurement of the outcome of subsequent
interventions (5).
CONCLUSIONS
The prevalence and burden of secondary antibody deficiency are
substantial and increasing. Secondary antibody deficiency
occurs in the majority of patients with hematological
malignancies, such as CLL and MM, either as a result of
disease-related effects on the immune system or as a side
effect of the treatment. Secondary antibody deficiency can
also emerge in less well-known at-risk patient populations,
such as patients undergoing SOT (due to post-transplantation
immunosuppressive therapy) (6), patients with neurological
conditions (129, 130) and patients with psychiatric conditions
(70). With the growth in new and more effective improved
therapies for malignancy and organ transplantation, the
incidence of secondary antibody deficiency is likely to increase
further, in particular when targeting different and multiple
components of B cell development and survival (Figure 2).
As the use of these newer, more effective immunosuppressive
medications becomes more prevalent, the resultant increased
survival in malignancy will be accompanied by a concomitant
increase in the prevalence of secondary antibody deficiency.
Given the diverse etiologies of secondary antibody deficiency,
healthcare practitioners from a wide range of specialties will
need to anticipate the possible immunological adverse effects
of the new therapeutic agents targeting the immune system.
Not surprisingly, secondary antibody deficiency is often missed
despite recurrent infections, resulting in delayed diagnosis and
intervention (168). Therefore, there is a real need for increased
awareness, screening, and improved monitoring of patients
at risk of developing secondary antibody deficiency to aid
early identification of these patients to avoid infection-related
morbidity and mortality.
Improved screening, such as by measuring calculated
globulin, is an important goal in the quest for identifying
secondary antibody deficiency as early as possible. In addition,
improved risk stratification and the use of biomarkers to
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identify the patients most likely to require interventions, such
as IgRT, within each patient population will be key. secondary
antibody deficiency patients will be no less individual than
PAD patients and should have the same access to treatments
once antibody failure has been demonstrated. The limited
evidence available in secondary antibody deficiency suggests
that there are significant similarities in management approaches
with those used for PAD. However, cohort and prospective
studies in secondary antibody deficiency are needed to support
decisions regarding patient selection and treatment with targeted
vaccination, prophylactic antibiotics, or IgRT. These studies
should also help to identify any distinctive clinical features that
may differ depending on the etiology of secondary antibody
deficiency (e.g., drug-induced vs. malignancy vs. specific disease
vs. transplantation setting) and how to optimize management of
this under-appreciated condition.
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